slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
227,701-227,730 of 319,975
12
Waterfall plot and spider plot showing patient-level clinical outcomes.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
13
The slide uses a before-after comparison for three specific patients (15B-01, 15B-15, 15B-17) to demonstrate clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
14
Includes a comparison table of historical data vs ELAHARE and a specific VIRO-15 clinical outcome table.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
15
The slide uses a bar chart to compare efficacy metrics (RECIST1.1, CA-125, PFS-6-month) across various clinical studies, with Genelux's VIRO-15 trial highlighted.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
16
The slide outlines a clinical trial protocol, specifically a randomized open-label study comparing an experimental arm to an active comparator arm.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
17
Includes Kaplan-Meier survival curves and patient cohort descriptions for two separate study groups.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
18
Includes specific patient case reports with RECIST criteria and biomarker data.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
19
Includes a bio for Benny Li, CEO of Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
20
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
21
The slide highlights the synergy between two existing therapies (TVI and Olvi-Vec) to create a new modality.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
22
The slide uses a hub-and-spoke style layout to categorize strategic pillars.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
23
The slide uses a combination of a bulleted list and a hub-and-spoke style visual representation of facility locations.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
24
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
25
The slide highlights key competitive moats including patent counts, freedom to operate, and regulatory protections.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
26
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
27
Includes specific footnotes regarding market close date, cash reporting date, and PIPE commitment details.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
28
The slide uses a dual-track visual: a list for past milestones and two curved arrows for future milestones.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
29
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
30
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
31
The slide lists key clinical advisors, highlighting their leadership roles in major oncology organizations and clinical trials.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
32
The slide uses two distinct chart types (spaghetti plot and waterfall plot) to validate the efficacy of the treatment.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
33
Includes a patient profile, a bar chart comparing PFS across treatment lines, and a longitudinal line chart tracking tumor size and CA-125 levels.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
34
Includes patient-specific histological evidence (Pt.#15A-01 and Pt.#15A-11) demonstrating the mechanism of action.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
35
The slide uses histology images and HALO infiltration histograms to demonstrate the mechanism of action and clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
36
The slide uses a combination of clinical timeline, patient history, and immunological data (ELISPOT) to correlate T-cell response with clinical outcome.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
37
The slide uses clinical study data (VIRO-15, NCT01443260) to validate the mechanism of action.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
01
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
02
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
03
Includes a table of net sales by product, a pie chart of sales mix, and bulleted financial highlights.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
04
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit